ASCO 2019 | COMBI-i findings

Georgina Long, MD, PhD, FRACP, from The University of Sydney, Sydney, Australia, discusses the findings of the COMBI-i trial (NCT02967692), which investigated the safety and efficacy of the combination of an anti-PD-1 antibody, spartalizumab (PDR001), a BRAF inhibitor, dabrafenib and a MEK inhibitor, trametinib in unresectable or metastatic melanoma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.